News release. Adverum Biotechnologies, Inc. November 4, 2022. https://investors.adverum.com/news/news-details/2022/Adverum-Biotechnologies-Presents-Positive-End-of-Study-Results-from-the-OPTIC-Trial-in-Wet-AMD-Including-Two-Year-Outcomes-Following-a-Single-Intravitreal-Injection-of-Ixo-vec-ADVM-022/default.aspx 2. Adverum Biotechnologies announces first subject dosed with ixo-vec in the phase 2 LUNA trial for the treatment of wet age-related macular degeneration. News release. Adverum Biotechnologies, Inc. September 14, 2022. https://investors.adverum.com/news/news-details/2022/Adverum-Biotechnologies-Announces-First-Subject-Dosed-with-Ixo-vec-in-the-Phase-2-LUNA-Trial-for-the-Treatment-of-Wet-Age-Related-Macular-Degeneration/default.aspx 3.